Clinical trial
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With…
NCT00099021 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00099021 |
|---|---|
| Title | Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia |
| Official title | A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Oral Leukoplakia |
| Intervention type | Drug |
| Interventions | pioglitazone hydrochloride |
| Enrollment | 21 |
| Start date | Jun 1, 2003 |
| Primary completion | Jun 27, 2008 |
| Completion | Jun 27, 2008 |
| First posted | Dec 9, 2004 |
| Last update posted | Feb 11, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: